Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcturus Therapeutics Holdings Inc (NQ: ARCT )

13.90 -0.36 (-2.52%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcturus Therapeutics Holdings Inc

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Arcturus Therapeutics to Attend Upcoming Investor Conferences
From Arcturus Therapeutics
Via Business Wire
Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded $115 Million in Grants from the Japanese Government
From Arcturus Therapeutics
Via Business Wire
Akamai Technologies, Array Technologies Music, HNI, PENN Entertainment And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded lower, with the Nasdaq Composite falling around 100 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Arcturus Therapeutics: Q1 Earnings Insights
Via Benzinga
Why Shares of Arcturus Therapeutics Dropped on Tuesday
The company saw revenue decline and net losses rise in the second quarter. 
Via The Motley Fool
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Energizer Holdings Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Nuburu, Inc. (NYSE: BURU) shares jumped 185.6% to $1.6593 after the company announced contract with NASA to demonstrate feasibility of power beaming in space using the company’s blue laser... 
Via Benzinga
Arcturus Therapeutics Announces Second Quarter 2023 Financial Update and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Dynavax Technologies Stock Sees Renewed Technical Strength
Dynavax Technologies shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 84. 
Via Investor's Business Daily
3 Biotech Stocks to Buy Before the Breakout
Explosive growth and rapid innovation lie ahead for these three biotechnology stocks, making them the ones to watch. 
Via InvestorPlace
Arcturus Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 7, 2023
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Analyst Initiates Arcturus: Sees Attractive Growth Trajectory with Vaccine Franchise Despite Competition
William Blair analyst Myles Minter has initiated coverage of Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) with an Outperform rating and a fair  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 24, 2023
Via Benzinga
Amicus Therapeutics Stock Scores Healthy Relative Strength Upgrade
On Thursday, Amicus Therapeutics stock got an upgrade to its Relative Strength (RS) Rating, from 78 to 81. 
Via Investor's Business Daily
3 Biotech Stocks for Getting Rich in 2023
These 3 biotech stocks have seen stable or growing revenue this year. This makes them companies to keep on your watchlist. 
Via InvestorPlace
Amicus Therapeutics Stock Sees Improving Market Leadership; Earns 81 RS Rating
On Monday, Amicus Therapeutics stock got an upgrade to its Relative Strength (RS) Rating, to 81, up from 74 a day earlier. 
Via Investor's Business Daily
UnitedHealth, Elanco Animal Health And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Abcam Stock Earns Relative Strength Rating Upgrade
A Relative Strength Rating upgrade for Abcam ADR shows improving technical performance. 
Via Investor's Business Daily
Why State Street Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers PainReform Ltd. (NASDAQ: PRFX) shares climbed 103% to $11.67. PainReform recently announced pricing of a $2.7 million concurrent registered direct offering and private placement. 
Via Benzinga
FibroGen Stock Joins Rank Of Stocks With RS Ratings Over 90
On Tuesday, FibroGen stock saw a positive improvement to its Relative Strength Rating, rising to 94 from 90 a day earlier. 
Via Investor's Business Daily
Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for ARCT-810, mRNA Therapeutic Candidate for Ornithine Transcarbamylase Deficiency
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Gilead Sciences Stock Reaches 80-Plus Relative Strength Rating Benchmark
On Thursday, Gilead Sciences stock had its Relative Strength (RS) Rating upgraded to 81, up from 78 a day earlier. 
Via Investor's Business Daily
Ionis Pharmaceuticals Stock Sees IBD RS Rating Climb To 79
The Relative Strength Rating for Ionis Pharmaceuticals stock moved into a new percentile Wednesday, as it got a lift from 65 to 79. 
Via Investor's Business Daily
Amicus Therapeutics Stock Scores Relative Strength Rating Upgrade; Hits Key Benchmark
One key metric to look for in a stock is an 80-plus RS Rating. Amicus Therapeutics stock hit that mark, with a jump from 74 to 82 Friday. 
Via Investor's Business Daily
Ultragenyx Pharm Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
Ultragenyx Pharm shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 81. 
Via Investor's Business Daily
Analyst's Vote of Confidence: Arcturus' COVID-19 Vaccine Efforts Set to Pay Off in Japan and Beyond
HC Wainwright has upgraded Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) from Neutral to Buy with  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2023
Via Benzinga
Unity Software, Tapestry, CIRCOR International And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded lower, with the Dow Jones dropping more than 300 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Arcturus Therapeutics Announces First Quarter 2023 Financial Update and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 9, 2023
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS